New guidelines for pregnancy care in multiple sclerosis, drawn up by a panel of UK experts, have been published this week.
They aim to reduce uncertainty about treatments that are safe and appropriate for pregnant and breastfeeding women with MS, and for couples affected by MS who are planning a pregnancy.
MS is usually diagnosed among 20-40 year olds, two thirds of whom are women. Around this age, both men and women might be planning to have children. At the same time, it is becoming increasingly clear that disease modifying drugs (DMDs) should be started as early as possible. Delaying DMD treatment until after having a family can lead to irreversible disability in the long term. For this reason, it makes sense to start discussing family planning and pregnancy early after diagnosis, alongside discussions about DMDs, if appropriate.
However, there is limited evidence available to guide these discussions, and so the MS Trust and a group of very experienced health professionals set out to develop a set of consensus guidelines to bring clarity to this area. The guidelines have been endorsed by the Association of British Neurologists, and have been reviewed by a panel of MS specialist nurses, neurologists, obstetricians, midwives and people with MS as part of the development process.
The guidelines bring together evidence from drug specific pregnancy registers as well as published peer reviewed research. They cover pre-pregnancy counselling and DMDs for men and women, MS management during pregnancy, delivery and anaesthetic options. The guidelines also give advice for the period after birth, for breastfeeding and for the use of DMDs after the birth.
We hope that the publication of these guidelines will enable health professionals to provide more informed guidance, support and care to people with MS when they are planning a family as well as during pregnancy and the post-natal period.
- Megan Roberts, Health Professionals Programme Manager, MS Trust
- Practical Neurology 2019;19:106-114. Full article UK consensus on pregnancy in multiple sclerosis: ‘Association of British Neurologists’ guidelines
Pregnancy and MS
For most women, MS does not make any significant difference to their pregnancy. Find out how to manage MS throughout your pregnancy.
DMT use in fathers to be
3 June 2014
A study examining the outcomes of pregnancies fathered by a man with multiple sclerosis taking a disease modifying drug.
Disease modifying drugs (DMDs)
DMDs are a group of treatments for people with relapsing MS which reduce the number and severity of any relapses you might experience.
Ofatumumab (Kesimpta) approved for relapsing MS in England and Wales
20 Apr 2021 - 00:00
The MS Trust is delighted that ofatumumab (Kesimpta) has been approved by NICE for people with active relapsing remitting multiple sclerosis.
Under-the-skin injection of Tysabri gets licence in UK and Ireland
16 Apr 2021 - 00:00
Under-the-skin (subcutaneous) injection of Tysabri (natalizumab) has been approved for UK and Ireland.
Ofatumumab (Kesimpta) gets UK licence for relapsing remitting MS
14 Apr 2021 - 00:00
The MHRA has granted marketing authorisation for ofatumumab (Kesimpta) for active relapsing remitting MS.